COMP <GO>
ASTH vs ICFI // EV/EBITDA & P/E VALUATION
Astrana Health Inc. (NASDAQ) VS. ICF International Inc. (NASDAQ) • 15-METRIC TALLY: ASTH 2
— ICFI 10
▲ EV/EBITDA & P/E VALUATION LEADER: ICFI
LAST: $36.62 (-0.14%) • MKT CAP: $1.82B
valuation
27.3x
LAST: $95.84 (+1.25%) • MKT CAP: $1.72B
valuation
14.5x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ASTH VS. ICFI)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ASTH | ICFI | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 37.20% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 4.60% | 8.10% | -3.50 | ICFI | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 27.3x | 14.5x | +12.80 | ICFI | /valuation <GO> |
| Free Cash Flow Yield | 5.75% | 8.25% | -2.50 | ICFI | /fcf-yield <GO> |
| Operating Margin | 2.50% | 7.80% | -5.30 | ICFI | /operating-margins <GO> |
| Net Profit Margin | 0.80% | 4.90% | -4.10 | ICFI | /net-margins <GO> |
| Revenue Growth (YoY) | 56.40% | -7.30% | +63.70 | ASTH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.43% | 0.60% | -0.17 | ICFI | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.54 | 2.87 | -0.33 | ICFI | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | ICFI | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.7 | 70.6 | -23.91 | ICFI | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 63.6x | 17.4x | +46.20 | ICFI | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.82B | $1.72B | $97.7M | ASTH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ASTH REV | ICFI REV | ASTH GROSS % | ICFI GROSS % | ASTH FCF | ICFI FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.18B | $1.87B | — | 37.2% | $104.5M | $141.9M |
| FY 2024 | $2.03B | $2.02B | — | 36.5% | $44.2M | $171.5M |
| FY 2023 | $1.39B | $1.96B | — | — | $68.2M | $152.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ASTH // BETA —
ICFI // BETA —